Indoco Works To Unblock Barriers To Growth
Executive Summary
India’s Indoco Remedies must address facility deficiencies highlighted by authorities in both the US and EU before it can revive its flagging formulations exports operation and restore top-line growth.
You may also be interested in...
Indoco Counts On Indian Market Bouncing Back
Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump. The Indian company continues to perform well internationally and grow overall.
Indoco FDA Warning Letter Will Take 12 Months To Resolve
India’s Indoco Remedies has received a new warning letter from the US Food and Drug Administration over its Goa manufacturing site. The company says it will take a year to fix the problems and the warning letter will delay approval of four ANDAs from the plant.
Pressure Mounts For German Tender Reforms
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.